Resurgex(R) Outperforms Major Brand in Tube Feeding Trial; Practitioners rate Resurgex more desirable than other products.

BASKING RIDGE, N.J. -- Millennium Biotechnologies, Inc., (OTCBB: MBTG), a research-based nutraceutical company and a pioneer in the emerging field of specialized nutritional supplements, is pleased to announce the results of a pilot study at the Northeast Center for Special Care (NCSC) on the ease of use, efficiency and acceptance of Resurgex(R) as an alternate nutritional supplement compared with other nationally known formulary brands.

The study consisted of administering approximately 1,000 servings of Resurgex to residents by facility practitioners over a period of 30 days. The study was a first head-to-head comparison with major brands. Resurgex was easier to dissolve, administer, and had greater consumer acceptance. The overall rating among the practitioners who conducted the study revealed a unanimous and outstanding level of acceptance, which exceeded the other major brands. The pilot project served to establish the potential of Resurgex(R) as the nutritional supplement of choice to replace several industry-leading nutritional supplements currently in wide used in the long-term-care profession.

NCSC serves multiply-impaired individuals with medically complex recovery needs such as brain injury, spinal cord injury, neurobehavioral disorders, and ventilator dependency.

"We are very pleased with the results of our first pilot study at Northeast Center for Special Care implementing Resurgex as a substitute for more traditional nutritional supplements. Resident, caregiver, and clinician satisfaction with these products is approaching 100%," said CEO Anthony Salerno of Healthcare Associates, one of New York State's largest long-term-care networks. "This is an outstanding product. We will be increasing and expanding use of this product to better meet the nutritional needs of the patients and residents in our healthcare facilities."

While Resurgex(R) and Resurgex-Plus(R) have successfully improved the quality of life and fatigue state in the immuno-compromised patient population, their acceptance and use in wound healing, complex medical recovery and rehabilitation demonstrates the versatility and usefulness in other clinical scenarios and sets another milestone for Millennium Biotechnologies," said Carl Germano, RD, CNS, CDN, senior vice president of product development and research for Millennium Biotechnologies. "This study points to the successful use of Resurgex(R) as a nutritional support formula that is capable of addressing the nutritional needs of the multiply-impaired patient.

Resurgex(R) and Resurgex-Plus(R) are the first multi-component nutritional supplements specifically designed to address the multiple nutritional needs of immuno-compromised individuals as an adjunct to their medical care. Such individuals often experience nutritional depletion, oxidative stress (free radical damage caused by medication or decreased weight/muscle loss (wasting) and fatigue. By supplying an array of specialized nutraceutical to the larger long term care sector, Resurgex(R) and Resurgex-Plus(R) can assist in reducing oxidative stress, increasing energy, building lean muscle and immune system support, thereby enhancing and supporting the process of rehabilitation and recovery.

The pilot study will be expanded by Healthcare Associates throughout its network of affiliates in long-term care, skilled nursing, home care and outpatient services; Resurgex(R) and Resurgex Plus(R) will be added to the formulary to meet the nutritional needs of people served in inpatient and outpatient settings throughout the network.

For additional information on the RESURGEX product line, please contact Jerry Swon, President and Chief Executive Officer at (908) 604 -2500 or via e-mail at [e-mail].

About Millennium Biotechnologies, Inc.

Millennium Biotechnologies, Inc. is a research-based nutraceutical company and a pioneer in the emerging field of specialized nutritional supplements. The company's flagship products, RESURGEX(TM) and RESURGEX Plus(TM), are designed to assist in strengthening cellular defense and supporting the immune system in patients with HIV/AIDS, Hepatitis C, cancer and other chronic illnesses. Millennium Biotechnologies also owns the exclusive medical-market rights to GliSODin(TM) (SOD/gliadin), the only orally effective form of the important antioxidant SOD (superoxide dismutase). Millennium Biotechnologies, Inc. is a wholly owned subsidiary of Millennium Biotechnologies Group, Inc., a publicly traded company (OTC BB: MBTG.OB). For more information about Millennium Biotechnologies, please call 908-604-2500 or visit www.milbiotech.com.

About Northeast Center for Special Care

The Northeast Center for Special Care is a unique, state-of-the-art inpatient special care center designed to serve individuals with medically complex conditions, including brain injury, spinal cord injury and ventilator dependency and neurobehavioral disorders. The mission of Northeast Center is to enable each individual it serves to achieve recovery, rehabilitation, and successful community re-entry. For more information about Northeast Center for Special Care, please call 845-336-3500 or visit www.northeastcenter.com.

This release includes certain forward-looking information that is based upon management's beliefs as well as on assumptions made by and data currently available to management. This information which has been, or in the future may be, included in reliance on the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, is subject to a number of risks and uncertainties, including but not limited to uncertainty as to market acceptance of Resurgex and Resurgex Plus and the factors identified in the Company's 10-KSB and other documents filed with the Securities and Exchange Commission. Actual results may differ materially form those anticipated in such forward-looking statements even if experience or future changes make it clear the any projected results expressed or implied therein may not be realized. The Company undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.